title: Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
abstract: Poor outcome of extramedullary disease in multiple myeloma patients and lack of outcome predictors prompt continued search for new markers of the disease. In this report, we show circulating microRNA distinguishing multiple myeloma patients with extramedullary disease from myeloma patients without such manifestation and from healthy donors. MicroRNA-130a was identified by TaqMan Low Density Arrays and verified by quantitative PCR on 144 serum samples (59 multiple myeloma, 55 myeloma with extramedullary disease, 30 healthy donors) in test and validation cohorts as being down-regulated in myeloma patients with extramedullary disease. Circulating microRNA-130a distinguished myeloma patients with extramedullary disease from healthy donors with specificity of 90.0% and sensitivity of 77.1%, patients with extramedullary disease from newly diagnosed multiple myeloma patients with specificity of 77.1% and sensitivity of 34.3% in the test cohort and with specificity of 91.7% and sensitivity of 30.0% in the validation cohort of patients. Circulating microRNA-130a in patients with extramedullary myeloma was associated with bone marrow plasma cells infiltration. Further, microRNA-130a was decreased in bone marrow plasma cells obtained from patients with extramedullary myeloma in comparison to bone marrow plasma cells of myeloma patients without such manifestation, but it was increased in tumor site plasma cells of patients with extramedullary disease compared to bone marrow plasma cells of such patients (p<0.0001). Together, our data suggest connection between lower level of microRNA-130a and extramedullary disease and prompt further work to evaluate this miRNA as a marker of extramedullary disease in multiple myeloma.
authors.affiliation: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
authors.forename: Lenka
authors.initials: L
authors.lastname: Besse
authors.affiliation: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
authors.forename: Lenka
authors.initials: L
authors.lastname: Sedlarikova
authors.affiliation: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Hematooncology, Faculty of Medicine University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic.
authors.forename: Fedor
authors.initials: F
authors.lastname: Kryukov
authors.affiliation: Institute of Clinical Biochemistry and Diagnostics, Faculty of Medicine and Faculty Hospital in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
authors.forename: Jana
authors.initials: J
authors.lastname: Nekvindova
authors.affiliation: Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
authors.forename: Lenka
authors.initials: L
authors.lastname: Radova
authors.affiliation: Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
authors.forename: Ondrej
authors.initials: O
authors.lastname: Slaby
authors.affiliation: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
authors.forename: Petr
authors.initials: P
authors.lastname: Kuglik
authors.affiliation: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
authors.forename: Martina
authors.initials: M
authors.lastname: Almasi
authors.affiliation: Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
authors.forename: Miroslav
authors.initials: M
authors.lastname: Penka
authors.affiliation: Department of Internal Medicine-Hematooncology, University Hospital Brno, Brno, Czech Republic.
authors.forename: Marta
authors.initials: M
authors.lastname: Krejci
authors.affiliation: Department of Internal Medicine-Hematooncology, University Hospital Brno, Brno, Czech Republic.
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Adam
authors.affiliation: Department of Internal Medicine-Hematooncology, University Hospital Brno, Brno, Czech Republic.
authors.forename: Ludek
authors.initials: L
authors.lastname: Pour
authors.affiliation: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
authors.forename: Sabina
authors.initials: S
authors.lastname: Sevcikova
authors.affiliation: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic; Department of Hematooncology, Faculty of Medicine University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic.
authors.forename: Roman
authors.initials: R
authors.lastname: Hajek
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood / Q000235:genetics; D001853:Bone Marrow / Q000473:pathology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000032:analysis / Q000097:blood* / Q000235:genetics; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000175:diagnosis / Q000235:genetics / Q000473:pathology*; D010950:Plasma Cells / Q000473:pathology*; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; C554019:MIRN130 microRNA, human; D035683:MicroRNAs